Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/13081
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Simmonds, P | en |
dc.contributor.author | Silberstein, M | en |
dc.contributor.author | McKendrick, J | en |
dc.date.accessioned | 2015-05-16T02:51:41Z | |
dc.date.available | 2015-05-16T02:51:41Z | |
dc.date.issued | 1993-06-01 | en |
dc.identifier.citation | Australian and New Zealand Journal of Medicine; 23(3): 264-7 | en |
dc.identifier.govdoc | 7688954 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/13081 | en |
dc.description.abstract | The accuracy of the assessment of patients with malignant disease and of their response to chemotherapy has been significantly improved with the routine availability of computerized tomography (CT) scanning. CT abnormalities, however, may be non-specific, especially after chemotherapy. Rebound enlargement of the thymus gland after chemotherapy induced atrophy is one cause of an abnormal thoracic CT scan on re-staging.This phenomenon has previously been reported mainly in relation to the treatment of lymphoma and germ cell cancers. This paper highlights the occurrence of thymic hyperplasia after chemotherapy in these and other tumour types.We discuss five cases including three patients with malignancies other than lymphoma in whom thymus enlargement occurred during or after intensive chemotherapy.Clear identification of the nature of CT abnormalities after chemotherapy, particularly in the mediastinum, is required prior to embarking on further anti-cancer treatments. | en |
dc.language.iso | en | en |
dc.subject.other | Adult | en |
dc.subject.other | Antineoplastic Combined Chemotherapy Protocols.adverse effects.therapeutic use | en |
dc.subject.other | Bleomycin.administration & dosage | en |
dc.subject.other | Dacarbazine.administration & dosage | en |
dc.subject.other | Doxorubicin.administration & dosage | en |
dc.subject.other | Hodgkin Disease.drug therapy | en |
dc.subject.other | Humans | en |
dc.subject.other | Male | en |
dc.subject.other | Mechlorethamine.administration & dosage | en |
dc.subject.other | Prednisone.administration & dosage | en |
dc.subject.other | Procarbazine.administration & dosage | en |
dc.subject.other | Thymus Hyperplasia.chemically induced.radiography | en |
dc.subject.other | Tomography, X-Ray Computed | en |
dc.subject.other | Vinblastine.administration & dosage | en |
dc.subject.other | Vincristine.administration & dosage | en |
dc.title | Thymic hyperplasia in adults following chemotherapy for malignancy. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Australian and New Zealand Journal of Medicine | en |
dc.identifier.affiliation | Ludwig Institute Oncology Unit, Austin Hospital, Melbourne, Victoria, Australia | en |
dc.description.pages | 264-7 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/7688954 | en |
dc.type.austin | Journal Article | en |
item.languageiso639-1 | en | - |
item.openairetype | Journal Article | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.